Article
Chemistry, Multidisciplinary
Wei Xiong, Bin Zhang, Haixin Yu, Liang Zhu, Lu Yi, Xin Jin
Summary: The study reveals that upregulated RRM2 in sunitinib-resistant RCC promotes resistance to TKIs, but the exact mechanism remains unclear. Additionally, RRM2 also impacts anti-tumor immune responses, and silencing RRM2 can enhance the efficacy of PD-1 blockade in renal cancer.
Review
Pharmacology & Pharmacy
Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing-Quan Wang, Shi-Jie Dai, Wen-fang He, Shou-Ye Li, Charles R. Ashby Jr, Zhe-Sheng Chen, Qiang He
Summary: Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, and targeted therapy with Sunitinib has become the main treatment option due to the lack of efficacy in radiation therapy and chemotherapy. However, many patients develop resistance to Sunitinib within months of therapy. In this review, we discuss the molecular mechanisms of Sunitinib resistance, strategies to overcome it, and potential predictive biomarkers.
DRUG RESISTANCE UPDATES
(2023)
Article
Oncology
Chia-Jung Busch, Christian Hagel, Benjamin Becker, Agnes Oetting, Nikolaus Moeckelmann, Conrad Droste, Christina Moeller-Koop, Melanie Witt, Markus Blaurock, Sonja Loges, Kai Rothkamm, Christian Betz, Adrian Muenscher, Till S. Clauditz, Thorsten Rieckmann
Summary: This study investigated the expression of Axl and Gas6 in head and neck squamous cell carcinoma, finding that high expression of Axl indicates a need for adjuvant radiotherapy after surgery. Gas6 expression was found to be a positive predictor of survival in patients receiving radiotherapy.
Article
Biochemistry & Molecular Biology
Yapeng Wang, Mou Peng, Yawen Zhong, Wei Xiong, Liang Zhu, Xin Jin
Summary: This study identified that elevated levels of E3 ligase RBCK1 contribute to the resistance of ccRCC cells to sunitinib, a targeted tyrosine kinase inhibitor. Inhibition of RBCK1 increased sensitivity to sunitinib and inactivated the AKT and MAPK signaling pathways. Mechanistically, RBCK1 promotes the degradation of ANKRD35 and destabilizes MITD1, leading to dysregulation of sunitinib in ccRCC cells.
Article
Oncology
Qing Kay Li, Tung-Shing Mamie Lih, Yuefan Wang, Yingwei Hu, Naseruddin Hoti, Daniel W. Chan, Hui Zhang
Summary: This study evaluated the diagnostic utility of 12 protein markers for assessing the aggressiveness of prostate cancer (PCa). Four proteins were found to be over-expressed in aggressive tumors, while three proteins showed stronger staining patterns in non-aggressive tumors. Combining different protein markers improved the accuracy of diagnosing the aggressiveness of PCa.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Tuomas Kaprio, Alexander M. Lindstrom, Tiina Rasila, Olga Saavalainen, Ines Beilmann-Lehtonen, Harri Mustonen, Caj Haglund, Leif C. Andersson
Summary: Colon cancer is a commonly diagnosed malignancy worldwide. The protein APCN has been identified as a potential novel independent prognostic marker in colon cancer, with high expression levels correlating with poor prognosis. This marker could potentially guide patient selection for more intense postoperative adjuvant treatment and follow-up.
BMC GASTROENTEROLOGY
(2021)
Article
Oncology
Zhenying Guo, Li Shen, Ningning Li, Xiaoxiao Wu, Canming Wang, Zheng Gu, Zhongjian Chen, Junping Liu, Weimin Mao, Yuchen Han
Summary: This study used bioinformatics to identify key genes in malignant mesothelioma, finding that Aurora-A could be an optimal diagnostic biomarker and a potential prognostic marker. Additionally, seven genes were identified as potential prognostic markers for MM.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jun Ito, Shigeki Sugawara, Takeo Tatsuta, Masahiro Hosono, Makoto Sato
Summary: The pretreatment of RCC cells with SAL can enhance the uptake and cytotoxic effects of molecular-targeted drugs, providing a theoretical basis for the development of new drugs for advanced RCC.
Article
Cell Biology
Zhongxiao Lin, Min Wen, Enxing Yu, Xiao Lin, Hua Wang, Jiayu Chen, ChaoJie Yao, Hengli Zhang, Junnan Ru, Kankai Wang, Ying Zhang, Lijie Huang, Qichuan Zhuge, Su Yang
Summary: This study analyzed the immune microenvironment in glioma samples and identified ANXA1 as an important prognostic indicator and immune marker for gliomas. ANXA1 expression was found to be associated with histopathological factors and correlated with the survival of glioma patients. In vitro experiments confirmed that antagonizing ANXA1 expression inhibited the invasion and migration capacities of glioma cells, suggesting its potential as an immunotherapeutic target for gliomas.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Eugen Bellon, Katharina Grupp, Tarik Ghadban, Michael Tachezy, Kai Bachmann, Jakob Robert Izbicki, Ronald Simon, Guido Sauter, Claudia Hube-Magg, Nathaniel Melling
Summary: LPCAT1 expression is increased in malignant esophageal tissue and correlated with undifferentiated tumor grading, but it is not associated with prognosis in esophageal cancer patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Pathology
Viktor Reiswich, Gonca Akdeniz, Maximilian Lennartz, Anne Menz, Viktoria Chirico, Claudia Hube-Magg, Christoph Fraune, Christian Bernreuther, Ronald Simon, Till S. Clauditz, Guido Sauter, Ria Uhlig, Andrea Hinsch, Simon Kind, Frank Jacobsen, Katharina Moeller, Stefan Steurer, Sarah Minner, Eike Burandt, Andreas H. Marx, Patrick Lebok, Till Krech, David Dum
Summary: The expression of Uroplakin 1B (Upk1b) was analyzed in various tumor types and normal tissues, revealing its presence in multiple tumor types, particularly in urothelial carcinoma. Low Upk1b expression was associated with high-grade and invasive tumor growth, as well as nodal metastasis.
Article
Oncology
Luc M. Berclaz, Annelore Altendorf-Hofmann, Hans Roland Duerr, Alexander Klein, Martin K. Angele, Markus Albertsmeier, Nina-Sophie Schmidt-Hegemann, Dorit Di Gioia, Thomas Knoesel, Lars H. Lindner
Summary: TOP2A and SIRT1 expression in high-risk soft tissue sarcoma patients can significantly impact chemotherapy efficacy and overall survival, serving as important predictive indicators.
Article
Oncology
Wei Li, Kun Ye, Xurui Li, Xinlin Liu, Mou Peng, Fang Chen, Wei Xiong, Yinhuai Wang, Liang Zhu
Summary: Our study identified a novel YY1/HDAC2/YTHDC1/ANXA1 axis that modulates the progression and chemosensitivity of ccRCC. Low expression of YTHDC1 in ccRCC tissues is associated with poor prognosis, and YTHDC1 inhibits renal cancer cell progression by downregulating the ANXA1/MAPK pathways. Additionally, the YTHDC1/ANXA1 axis influences the sensitivity of tyrosine kinase inhibitors, and HDAC2 inhibitors can resensitize ccRCC to these inhibitors through the complex.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Harrison Sicheng Lin, Qiang Ding, Zsuzsanna Lichner, Sung Sun Kim, Rola Saleeb, Mina Farag, Ashley Di Meo, Pamela Plant, Mirit Kaldas, Georg Arnold Bjarnason, George Makram Yousef
Summary: Resistance to sunitinib treatment is a common issue in metastatic renal cell carcinoma, and individualizing treatment protocols could be the key to solving this problem. Through experiments, it was discovered that alternative treatment schedules could delay cancer progression and result in distinct morphological changes in the tumor compared to traditional treatment schedules.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin, Liang Zhu
Summary: Our study identified that NFAT1, when overexpressed in RCC, was associated with poor prognosis and could enhance tumor growth by increasing PD-L1 expression. Additionally, NFAT1 was found to be stabilized in sunitinib-resistant RCC through hyperactivation of the PI3K/AKT/GSK-3 beta signaling pathway. The downregulation of FBW7, which promotes NFAT1 degradation, was induced by FOXA1 and SETD2 in sunitinib-resistant RCC, contributing to immune response modulation. This study reveals a new role for the FBW7/NFAT1 axis in RCC response to TKIs and ICIs, suggesting NFAT1 as a potential therapeutic target for RCC treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Artur Mezheyeuski, Maja Bradic Lindh, Tormod Kyrre Guren, Anca Dragomir, Per Pfeiffer, Elin H. Kure, Tone Ikdahl, Eva Skovlund, Sara Corvigno, Carina Strell, Kristian Pietras, Fredrik Ponten, Jan Mulder, Camilla Qvortrup, Anna Portyanko, Kjell Magne Tveit, Bengt Glimelius, Halfdan Sorbye, Arne Ostman
Article
Oncology
Marjut Niinivirta, Gunilla Enblad, Per-Henrik Edqvist, Fredrik Ponten, Anca Dragomir, Gustav J. Ullenhag
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2017)
Article
Multidisciplinary Sciences
Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Ponten, Karin Jirstrom, Bengt Glimelius, Jakob Eberhard
Article
Pathology
Artur Mezheyeuski, Carina Strell, Ina Hrynchyk, Tormod Kyrre Guren, Anca Dragomir, Tatyana Doroshenko, Oksana Pashkova, Julia Gorgun, Kseniya Ruksha, Per Pfeiffer, Elin H. Kure, Halfdan Sorbye, David Edler, Anna Martling, Bengt Glimelius, Arne Ostman, Anna Portyanko
Article
Oncology
Jessica Cedervall, Anca Dragomir, Falk Saupe, Yanyu Zhang, Johan Arnlov, Erik Larsson, Anna Dimberg, Anders Larsson, Anna-Karin Olsson
Article
Endocrinology & Metabolism
Katarina Lindahl, Eva Astrom, Anca Dragomir, Sofie Symoens, Paul Coucke, Sune Larsson, Eleftherios Paschalis, Paul Roschger, Sonja Gamsjaeger, Klaus Klaushofer, Nadja Fratzl-Zelman, Andreas Kindmark
Editorial Material
Clinical Neurology
Amalia Feresiadou, Olivera Casar-Borota, Anca Dragomir, Carola Hedberg Oldfors, Erik Stalberg, Anders Oldfors
NEUROMUSCULAR DISORDERS
(2018)
Article
Multidisciplinary Sciences
Halfdan Sorbye, Anca Dragomir, Magnus Sundstrom, Per Pfeiffer, Ulf Thunberg, Monica Bergfors, Kristine Aasebo, Geir Egil Eide, Fredrik Ponten, Camilla Qvortrup, Bengt Glimelius
Article
Oncology
Kristine O. Aasebo, Anca Dragomir, Magnus Sundstrom, Artur Mezheyeuski, Per-Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye
Article
Biotechnology & Applied Microbiology
Christophe Avenel, Anna Tolf, Anca Dragomir, Ingrid B. Carlbom
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2019)
Article
Oncology
Artur Mezheyeuski, Fredrik Ponten, Per-Henrik Edqvist, Magnus Sundstrom, Ulf Thunberg, Camilla Qvortrup, Per Pfeiffer, Halfdan Sorbye, Bengt Glimelius, Anca Dragomir
Article
Oncology
Luis Nunes, Kristine Aasebo, Lucy Mathot, Viktor Ljungstrom, Per-Henrik Edqvist, Magnus Sundstrom, Anca Dragomir, Per Pfeiffer, Adam Ameur, Fredrik Ponten, Artur Mezheyeuski, Halfdan Sorbye, Tobias Sjoblom, Bengt Glimelius
Article
Oncology
J. Cedervall, M. Herre, A. Dragomir, F. Rabelo-Melo, A. Svensson, C. Thalin, A. Rosell, V Hjalmar, H. Wallen, H. Lindman, G. Pejler, E. Hagstrom, M. Hultstrom, A. Larsson, A. K. Olsson
Summary: This study investigates the role of neutrophil extracellular traps (NETs) in myocardial inflammation and tissue damage in treatment-naive cancer patients. The findings suggest that NETs contribute to inflammation and myocardial stress during malignancy, and removing NETs may prevent cardiac inflammation and dysfunction in cancer patients.
Article
Oncology
Marjut Niinivirta, Gunilla Enblad, Cecilia Lindskog, Fredrik Ponten, Anca Dragomir, Gustav J. Ullenhag